Bayer, Janssen’s Xarelto cuts risk of amputation, death

13th November 2017 Uncategorised 0

Two new analyses of data from the COMPASS trial show that Bayer and Janssen’s blood thinner Xarelto significant cut the amputation rate for patients with peripheral artery disease and also a 23 percent reduction in deaths in patients with coronary artery disease.

More: Bayer, Janssen’s Xarelto cuts risk of amputation, death
Source: News